CDKN2A homozygous deletion, PDGFRA amplification, and CDK4 amplification were found to be associated with shorter progression‐free survival (PFS) and overall survival (OS) in WHO grade II–III astrocytoma with IDH‐mutant.3 The gene discussed is CDKN2A; the disease is astrocytoma (excluding glioblastoma).